In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
The following faculty have reported relationships with ineligible companies:
Paolo F. Caimi, MD, faculty for this educational event, is a contract researcher for Genentech, and ADC Therapeutics; and receives consulting fees from ADC Therapeutics, Genentech, Gilead, Incyte, Bristol Myers Squibb, Takeda, Lilly, MEI Pharma, Novartis, and Genmab.
Peter Riedell, MD, faculty for this educational event, is a contract researcher for Bristol Myers Squibb, Kite Pharma, Inc/Gilead, MorphoSys, Calibr, Tessa Therapeutics, Fate Therapeutics, Xencor, and Novartis; and receives consulting fees from AbbVie, ADC Therapeutics, Novartis Pharmaceuticals Corporation, Bristol Myers Squibb, Janssen, BeiGene, Karyopharm Therapeutics Inc., Takeda Pharmaceutical Company, Kite Pharma, Inc./Gilead, Sana Biotechnology, Nektar Therapeutics, Nurix Therapeutics, Intellia Therapeutics, and CVS Caremark.